# A Phase II Clinical Trial of Chiglitazar for NASH

> **NCT05193916** · PHASE2 · COMPLETED · sponsor: **Chipscreen Biosciences, Ltd.** · enrollment: 104 (actual)

## Conditions studied

- NASH

## Interventions

- **DRUG:** chiglitazar sodium tablets
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05193916
- **Lead sponsor:** Chipscreen Biosciences, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-21
- **Primary completion:** 2024-01-02
- **Final completion:** 2024-01-02
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2024-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05193916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05193916, "A Phase II Clinical Trial of Chiglitazar for NASH". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05193916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*